Literature DB >> 28457008

A life-threatening ruxolitinib discontinuation syndrome.

Giacomo Coltro1,2,3, Francesco Mannelli1, Paola Guglielmelli1,2, Annalisa Pacilli1,2, Alberto Bosi3, Alessandro Maria Vannucchi1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28457008     DOI： 10.1002/ajh.24775

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  15 in total

Review 1.  MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too.

Authors:  Anna Falanga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.

Authors:  Giuseppe G Loscocco; Alessandro M Vannucchi
Journal:  Int J Hematol       Date:  2022-03-29       Impact factor: 2.490

3.  Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.

Authors:  Liping Dou; Bo Peng; Xin Li; Lu Wang; Mingyu Jia; Lingmin Xu; Fei Li; Daihong Liu
Journal:  Trials       Date:  2022-06-06       Impact factor: 2.728

4.  Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.

Authors:  Gérard Socié; Jean-Jacques Kiladjian; Marie Robin; Raphael Porcher; Corentin Orvain; Jacques-Olivier Bay; Fiorenza Barraco; Anne Huynh; Amandine Charbonnier; Edouard Forcade; Sylvain Chantepie; Claude Bulabois; Ibrahim Yakoub-Agha; Marie Detrait; David Michonneau; Pascal Turlure; Nicole Raus; Françoise Boyer; Felipe Suarez; Laure Vincent; Stéphanie N Guyen; Jérôme Cornillon; Alban Villate; Brigitte Dupriez; Bruno Cassinat; Valérie Rolland; Marie Hélène Schlageter
Journal:  Bone Marrow Transplant       Date:  2021-03-25       Impact factor: 5.174

5.  Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Authors:  Ayalew Tefferi; Daniela Barraco; Terra L Lasho; Sahrish Shah; Kebede H Begna; Aref Al-Kali; William J Hogan; Mark R Litzow; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Blood Cancer J       Date:  2018-03-07       Impact factor: 11.037

6.  Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.

Authors:  Denis Tvorogov; Daniel Thomas; Nicholas P D Liau; Mara Dottore; Emma F Barry; Maya Lathi; Winnie L Kan; Timothy R Hercus; Frank Stomski; Timothy P Hughes; Vinay Tergaonkar; Michael W Parker; David M Ross; Ravindra Majeti; Jeffrey J Babon; Angel F Lopez
Journal:  Sci Adv       Date:  2018-11-28       Impact factor: 14.136

Review 7.  Lessons learned from the study of human inborn errors of innate immunity.

Authors:  Giorgia Bucciol; Leen Moens; Barbara Bosch; Xavier Bossuyt; Jean-Laurent Casanova; Anne Puel; Isabelle Meyts
Journal:  J Allergy Clin Immunol       Date:  2018-08-01       Impact factor: 10.793

Review 8.  Management of myelofibrosis after ruxolitinib failure.

Authors:  Claire N Harrison; Nicolaas Schaap; Ruben A Mesa
Journal:  Ann Hematol       Date:  2020-03-20       Impact factor: 3.673

9.  Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases.

Authors:  Morgan K Groover; Jillian M Richmond
Journal:  F1000Res       Date:  2020-10-05

10.  Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients.

Authors:  Annabelle J Anandappa; Gabriela S Hobbs; Bimalangshu R Dey; Areej El-Jawahri; Matthew J Frigault; Steven L McAfee; Paul V O'Donnell; Thomas R Spitzer; Yi-Bin Chen; Zachariah DeFilipp
Journal:  Oncologist       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.